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Summary The incidence of antifungal resistance is on the increase worldwide and novel drugs are
constantly being developed to counter this trend. One hundred and sixteen clinical
isolates of Candida albicans were collected from Lebanese hospitals in order to first
determine the degree of resistance of Lebanese isolates to four common azoles:
fluconazole (FL), itraconazole (IT), ketoconazole (KE), and voriconazole (VO), in
addition to amphotericin B (AP) and caspofungin (CS) through the Epsilometer test
method and second, determine any relationship between the allelic compositions of the
mating type loci (MTLa, MTL a, MTLa ⁄ a) with drug resistance. Results showed that
resistance, among C. albicans isolates, was the highest with 12% for IT, followed by
7.7% for VO, 6% for KE, 5% for FL, 1.7% for AP and 0% for CS. Three isolates (2.6%)
were resistant to all azoles tested, including one that was resistant to all drugs used
except CS. Eleven isolates were homozygous at the MTL locus (9.5%), five of which
(45%) were resistant to at least one antifungal drug whereas 14 of the 105
heterozygous strains (13%) exhibited similar resistance (P = 0.02), indicating a strong
correlation between MTL locus homozygosity and resistance.
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Introduction
Candida albicans is a dimorphic opportunistic pathogen
that exists commensally in warm-blooded animals
including humans. It colonises mucosal surfaces of the
oral cavity, digestive tract or genitourinary system of
healthy individuals and is capable of causing a variety of
infections depending on the nature of the defect in the
host.1,2 Candidiasis due to C. albicans is the most
common mycosis associated with human immunodefi-
ciency virus infection, occurring in up to 90% of
patients.3 Candida infections have dramatically
increased in the last decade because of immunosup-
pressive treatments, long-term catheterisation,
prolonged use of broad-spectrum antibiotics and longer
survival of immunologically compromised individuals.4
Candida species are the fourth most common cause of
nosocomial bloodstream infections in the United States,
with C. albicans the most commonly encountered
species.1,5 However, statistical data on the ranking of
C. albicans infections in Lebanon are absent.
When compared to the number of antibacterial drugs,
antifungal drugs are very limited1,6–8 because many
potential antifungal drug targets have homologues of
similar function and susceptibility to inhibition in
humans and the toxic side effects dramatically reduce
the number of antifungal agents that can be used
therapeutically.1 There are five major classes of systemic
antifungal compounds currently in clinical use: poly-
enes, azoles, allylamines, fluoropyrimidines, and echino-
candins and pneumocandins. The polyenes, mainly
amphotericin B (AP) are fungicidal and have the
broadest spectrum of activity of any clinically useful
antifungal drug but can cause nephrotoxicity.9 The
azoles are fungistatic and have a broad spectrum of
activity with few side effects with fluconazole (FL),
itraconazole (IT), and voriconazole (VO), being the most
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frequently utilised.1,8,10,11 Fluconazole is the preferred
azole because of its high oral bioavailability, good safety
profile and broad efficacy against most pathogenic
yeast.3,12 Itraconazole and some newer azoles like VO
are also active against non-yeast fungal infections. Up to
a third of all AIDS patients retain an azole-resistant
C. albicans isolate orally.13,14 The allylamines are fungi-
cidal, have a broad spectrum of in vitro activity and
limited clinical efficacy because of poor pharmacokinet-
ics, with terbinafine being the only systemic antifungal in
this class in clinical use.1,9 The fluoropyrimidines, such
as 5-fluorocytosine are fungicidal with a limited spec-
trum of activity.1,6 Finally, the fifth and the most recent
class, the echinocandins and pneumocandins, is fungi-
cidal. Caspofungin (CS) (MK-0991), one of only three
echinocandins licensed for use, is available as intrave-
nous injections and cause minimal host toxicities.1,10,15
Caspofungin, has been approved for the treatment of
oropharyngeal and oesophageal candidiasis,16 and inva-
sive aspergillosis in patients not responding or intolerant
to other antifungal drugs.17,18 Recently, Laverdie`re et al.
[19] reported, for the first time, the progressive loss of
activity of echinocandin drugs against clonally related
C. albicans isolates following long-term clinical exposure
to this new class of antifungal agents.
To date, and based on a one year survey which we
conducted of five major Lebanese pharmacies located in
Beirut, encompassing around 500 antifungal prescrip-
tions, three categories of azole antifungal agents with
diverse trademarks dominate all antifungal prescrip-
tions. These are FL (82%), followed by ketoconazole (KE)
(11%) and IT (7%).
Candida species have the ability to switch phenotypes
and alternate between several different forms where
each form expresses a unique set of genes and cell
morphologies.3,12 One such system, involves a reversible
white-opaque transition.20 The diploid yeast C. albicans
possesses a single mating type-like (MTL) locus on
chromosome 5, which is normally heterozygous a ⁄ a.21
TheMTL locus on one of the chromosome 5 homologues
contains the MTLa1 gene while the other homologue
containsMTLa1 andMTLa2 genes.20,22,23 The MTLa1p-
MTLa2p complex, in MTL-heterozygotes forms a hete-
rodimer that represses mating. In order to mate,
C. albicans must undergo MTL-homozygosis to a ⁄ a or
a ⁄ a.23 MTL-zygosity regulates not only mating24–26
but also phenotypic switching,21 because only MTL-
homozygotes can undergo the white-opaque transition.
Lockhart [21] revealed that in nature, the majority of
isolates are MTL-heterozygous and only a minority of
clinical isolates are MTL-homozygous, with disease-
associated isolates switching at higher rates than
commensal isolates.16 It has been demonstrated that
switching can occur at sites of infection and between
episodes of recurrent vaginitis, and that it may function
to generate variability in commensal and infecting
populations for adaptive reasons.27 In a cutaneous
mouse model, opaque cells are more virulent than white
cells, while in a systemic mouse model white cells are
more virulent than opaque cells.20,28,29 To date, the
findings on the relationship between MTL homozygosity
and drug resistance remains contradictory. A study
showed that homozygosity at the C. albicans MTL locus is
associated with azole resistance,30 whereas another
study revealed that in C. albicans, drug resistance is not
directly affected by mating type locus zygosity.31
This study involves the collection of a large number of
C. albicans hospital isolates from different hospitals in
Lebanon to test for their susceptibility against different
antifungal drugs that are either currently in clinical use,
or recently approved and released for clinical use using
the Epsilometer test method. Our selection of antifungal
drugs encompassed the most pharmaceutically pre-
scribed antifungal drugs in Lebanon notably FL, KE and
IT. Furthermore, imidazole, VO and the novel echino-
candin, CS were chosen for this study as there are no
published data of them being utilised in Lebanon so far,
although their use by a small number of hospitals
cannot be ruled out. This study will be performed in an
effort to recommend their use by a wider number of
hospitals if the antifungal susceptibility tests are deemed
satisfactory. Moreover, as there are contradictory data
on the correlation between MTL homozygosity and drug
resistance, we will determine the MTL locus genotype of
each isolate by amplifying the a1, a1, and a2 genes in
an effort to determine a possible correlation between
homozygosity at the C. albicans MTL locus and resis-
tance to azole antifungal drugs.
Materials and methods
Hospital isolates
A total of 116 random clinical isolates labelled as
C. albicans were collected from different hospitals in
Beirut such as: Saint Georges Hospital (52 isolates),
American University of Beirut Medical Center (49
isolates), Hotel-Dieu de France (seven isolates), Rizk
Hospital (six isolates) and Sahel General Hospital (two
isolates). The samples were recovered from a variety of
niches as can been seen in Table 1. Although most
hospitals refused to disclose clinical details on patients
history including possible antifungal drug therapy,
their medical ⁄ health conditions varied from common
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superficial infection to severe diseases such as cardiac
arrest, cancer and AIDS (requiring antibiotic therapy).
Species identification
All isolates were confirmed as C. albicans by C. albicans
primer specific microsatellite DNA amplification (data
not shown).
Quality control (QC) reference strain
The CLSI QC strains Candida parapsilosis ATCC 22019
and C. albicans ATCC 9002832–37 were used as reference
strains in the antifungal susceptibility tests.
Growth and storage of isolates
All hospital isolates were initially cultured and purified
on Tryptone Soy Agar (Himedia, Mumbai, India).
Purified colonies were maintained at )80C in Potato
Dextrose Broth (Himedia), containing 20% glycerol for
long term storage. Fresh inoculants from the )80C
stock were grown on Potato Dextrose Agar plates
(Oxoid, Basingstoke, UK) at 30C as needed.
Antifungal susceptibility media preparation
For azoles and AP, High Resolution Medium (Oxoid)
was utilised, while RPMI1640 medium buffered with
165 mmol l)1 MOPS (Biowhittaker, Brussels, Belgium)
was used for CS, as suggested by the manufacturer. Both
media were prepared according to the manufacturers
instructions and poured on to 150 mm agar plates with
a depth of 4 ± 0.5 mm.
Antifungal susceptibility testing
The antifungal susceptibility test was performed using
the E-test method. E-test strips of FL, VO, KE, IT, AP, and
CS were supplied by AB Biodisk, Solna, Sweden.
Inoculum preparation, inoculation and strip application
were performed according to the manufacturers
instructions. Minimal inhibitory concentration (MIC)
readings were recorded after 48-h incubation at 35 C.
As recommended by the manufacturer, AP MICs were
read as the lowest concentration on the E-test strip at
which there was 100% inhibition i.e., at the point
where the border of the elliptical inhibition zone
intersected the strip, whereas CS and azole MICs were
read as the least concentration at which there was 80%
growth inhibition or where there was a significant
decline in growth. Furthermore, all resistant isolates
were re-tested utilising the Sensititre YeastOne with CS
and posaconazole broth microdilution plates, according
to the manufacturers instructions (Trek Diagnostic
Systems, Cleveland, OH, USA).
MIC interpretive breakpoints for antifungal agents
The MIC interpretive criteria for FL and IT were as
follows: susceptible (S), £8 lg ml)1; susceptible-dose
dependent (S-DD), 16–32 lg ml)1; and resistant (R),
‡64 lg ml)1 for FL, and (S), £0.125 lg ml)1; R,
‡1 lg ml)1; with intermediary MICs considered as
S-DD, for IT.33,38 Although interpretive breakpoints
have not yet been established for VO, KE, AP, and CS,
we have selected the following criteria for purposes of
comparison in our study: S, £1 lg ml)1; R, ‡2 lg ml)1
for VO,35,39 R, ‡0.38 lg ml)1 for AP,40,41 and R,
‡1 lg ml)1 for KE, as its pharmacokinetics is similar to
IT. For CS, no interpretive criteria have been established
but an MIC value of >1 lg ml)1 is commonly used by
most researchers to denote resistance.42
Quality control
The control limits for the C. parapsilosis ATCC 22019
strain were FL: 1–8 lg ml)1; VO: 0.016–
0.064 lg ml)1; KE: 0.032–0.125 lg ml)1; IT:
0.064–0.25 lg ml)1; AP: 0.25–1 lg ml)1; and CS:
0.25–2 lg ml)1 and for C. albicans ATCC 90028: FL:
0.125–0.5 lg ml)1; VO: 0.004–0.016 lg ml)1; KE:
0.008–0.032 lg ml)1; IT: 0.064–0.25 lg ml)1; AP:
0.125–0.5 lg ml)1; and CS: 0.064–0.25 lg ml)1. Our
Table 1 Isolation frequency and location
Frequency Location
35 Sputum
24 Stool
17 Urine
9 Deep tracheal aspirate
8 Vagina
8 Bronchial alveolar wash
5 Wound
2 Abdominal fluid
1 Tooth abscess
1 Pus
1 Penile swab
1 Peritoneal fluid
1 Nail
1 Blood
1 Jackson–Pratt drainage
1 Cerebrospinal fluid
Table shows the frequency of isolation and the location of all 116
Candida albicans samples. Note that sputum, stool and urine con-
stitute around two-thirds of all isolates.
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MIC values were within the control limits for all
antifungal drugs tested.
DNA extraction
Pure genomic DNA was extracted from all 116 strains
as described previously.43
MAT locus amplification
Fifty nanograms of pure genomic DNA was used to
amplify the a1, a1 and a2, genes, by PCR, using the
following primers (5¢ ﬁ 3¢): F-AAGAATGAAGACAAC
GAGG3¢, and R-CGTGTTTTTCTGCTATCAATTCC for a1;
F-TACATTCTGGTCGCGATGCTC and R-GTAATCC
AAAGCCTCGCATAA for a1; and F-ATGAATTCACAT
CTGGAGGC and R-CTGTTAATAGCAAAGCAGCC for
a2. (F denotes the forward primer and R the reverse
primer). Fragment sizes obtained were 535, 423, and
615 bp respectively.30 Reaction mixtures were typically
heated for 5 min at 94 C, followed by 30 cycles of 30 s
at 94 C, 1 min at 60 C and 1 min at 72 C. After a
final incubation of 10 min at 72 C, reaction mixtures
were stored at 4 C.
Statistical analysis
Chi-squared tests were performed on the data collected
using SIGMASTAT 3.1 computer software (Systat Software
Inc, Richmond, CA, USA) to assess the significance of
any discrepancy.
Results
Antifungal resistance
All 116 isolates were tested against the six above-
mentioned antifungal drugs. One isolate was recovered
per patient with only two exceptions from Saint Georges
Hospital, where two isolates were recovered from one
patient and another three from a second patient.
However, the drug susceptibility profiles for isolates
retrieved from the same individual were different,
suggesting that each isolate was unique and the patient
did not suffer multiple infections from the same isolate,
which could have skewed the data presented. A
summary of their MICs, geometric mean MIC and MIC
ranges, is presented in Tables 2 and 3. As far as azoles
are concerned, and according to the MIC interpretive
breakpoints for FL, 110 samples were S, £8 lg ml)1;
none of the samples were S-DD, 16–32 lg ml)1; and six
samples were R, ‡64 lg ml)1. Similarly for IT, 90
samples were S, £0.125 lg ml)1; 12 samples were
S-DD, 0.25 to 0.75 lg ml)1; 14 samples were (R
‡1 lg ml)1). By using the putative breakpoints for VO
of S with an MIC £1 lg ml)1 and R with an MIC
‡2 lg ml)1, with no intermediate or S-DD category, it
was found that for the 116 isolates tested, 107 were
sensitive. Of the nine resistant C. albicans isolates, eight
had MICs ‡32 lg ml)1 and one isolate had an MIC of
3 lg ml)1. In the absence of interpretive criteria for KE
and by utilising the MIC ‡1 lg ml)1 to be a breakpoint
for resistance, it was noted that seven isolates were
resistant, four of which possessed an MIC >32 lg ml)1
reflecting clear resistance. To confirm the azole resis-
tance phenotype, isolates were re-tested by a second
technique utilising the Sensititre Yeast One kit. Resis-
tance patterns were comparable with no statistically
significant discrepancies observed. By assuming that the
AP breakpoint for resistance as MIC ‡0.38 lg ml)1, it
was noted that only two isolates were resistant.
As far as CS, none of the isolates displayed an MIC
that could exceed the maximum drug concentration on
the E-test strip to reflect clear resistance because all
isolates exhibited MICs <1 lg ml)1 and were hence
deemed sensitive.
Table 2 Antifungal MIC distribution vs. isolates
Antifungal
Number of isolates with the following MIC range (lg ml)1)
0.002–0.016 0.023–0.032 0.047–0.094 0.125–0.25 0.38–0.75 1–2 3–6 8–16 >32 >256
FL 0 0 9 26 47 20 7 1 0 6
VO 54 21 22 10 0 0 1 0 8 0
KE 67 21 12 9 0 2 1 0 4 0
IT 29 19 26 16 12 7 2 0 5 0
AP 4 9 45 56 1 1 0 0 0 0
CS 1 6 65 42 2 0 0 0 0 0
FL, fluconazole; VO, voriconazole; KE, ketoconazole; IT, itraconazole; AP, amphotericin B; CS, caspofungin; MIC, minimal inhibitory
concentration.
For the sake of clarity, MIC values were categorised instead of showing the value for each individual isolate.
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Mating type-like loci
Polymerase chain reaction amplification at the a1, a1
and a2 loci was performed. Isolates that lacked either
the a1 or the a1 and a2 alleles were deemed homozy-
gous. One hundred and five isolates were heterozygous
and 11 were homozygous. Of the 11 homozygous
isolates, 10 were MTLa and one was MTLa. Table 4
shows the distribution of MTL homozygous isolates with
respect to the location of infection and azole drug
resistance. Chi-squared analysis of these results gener-
ated a P-value of 0.02 indicating a strong correlation
between resistance and MTL homozygosity.
Discussion
In this study, we determined the susceptibility of
C. albicans and other yeast to five commonly used
antifungal agents (FL, VO, KE, IT and AP) in addition to
CS, which has been approved for clinical use relatively
recently. E-test on solid media was utilised as an
alternative test to the broth methods as it is easier to
perform than the macro and microbroth methods, and
more convenient and reliable in clinical diagnostic
laboratory testing.44
Based on the defined MIC interpretive breakpoints for
FL and IT, few resistant C. albicans isolates were found
against FL (5.17%) than IT (12.06%). However, by
utilising the putative interpretive breakpoints for VO,
and AP, we found that 7.75% of the C. albicans isolates
were resistant to VO and only 1.7% was resistant to AP.
Even though no MIC interpretive criteria have been
defined for KE and CS, KE MICs of ‡1 were observed for
seven isolates (6.03%); three strains had MICs of 1.5, 2
and 3 lg ml)1 and the remaining four had MICs
>32 lg ml)1, which reflects clear resistance. As for
CS, most laboratories use an MIC >1 lg ml)1 to
designate susceptibility and hence all our strains are
susceptible. Thus the order of antifungal drug resistance
against C. albicans is as follows: IT > VO > KE >
FL > AP > CS.
In vitro studies have suggested that cross-resistance
may occur with FL and other azole compounds.45,46
The mechanism for such cross-resistance has been
clearly demonstrated in a number of studies and most
often involves the upregulation of genes encoding the
ATP-binding cassette efflux transporters, or CDR
pumps.47–49 Cross-resistance to azole antifungal agents
was noted for eight isolates including three that were
completely resistant to all azoles tested. Interestingly,
whenever resistance to FL was observed, resistance to
VO was also seen. This could be attributed to the fact
that these two triazoles are structurally related.50
Thus, resistance to VO might be considered secondary
Table 3 MIC ranges of antifungal agents on Candida albicans iso-
lates
Antifungal agent n
MIC range
(lg ml)1)
Geometric
mean MIC
Fluconazole 116 0.047–>256 0.70
Voriconazole 116 <0.002–>32 0.04
Ketoconazole 116 0.002–>32 0.03
Itraconazole 116 0.002–>32 0.08
Amphotericin B 116 0.008–1 0.1
Caspofungin 116 <0.002–0.5 0.09
MIC, minimal inhibitory concentration.
Note that fluconazole has the highest geometric mean MIC, while
ketoconazole has the lowest.
Table 4 Comparison of MTL-homo-
zygosity to drug resistance
Isolate location MTL genotype
MICs (lg ml)1) of azoles
FL VO KE IT
Tooth abscess a 0.094 (S) 0.003 (S) 0.004 (S) 0.004 (S)
Urine a 4 (S) 0.032 (S) 0.032 (S) 2 (R)
BAW a 0.064 (S) 0.032 (S) 0.016 (S) 0.016 (S)
BAW a 0.047 (S) <0.002 (S) 0.002 (S) 0.002 (S)
Peritoneal fluid a 6 (S) 0.125 (S) 0.25 (S) 0.75 (SDD)
Sputum a 0.25 (S) 0.008 (S) 0.006 (S) 0.023 (S)
Stool a 1 (S) 0.032 (S) 0.023 (S) 0.032 (S)
DTA a 4 (S) 0.094 (S) 0.25 (S) 1 (R)
Urine a >256 (R) 0.094 (S) 0.32 (S) 0.25 (SDD)
DTA a >256 (R) >32 (R) >32 (R) >32 (R)
Sputum a 6 (S) 0.19 (S) 0.064 (S) 1 (R)
MIC, minimum inhibitory concentration; FL, fluconazole; VO, voriconazole; KE, ketoconaz-
ole; IT, itraconazole; (R), resistant; (S), susceptible; SDD, susceptible dose dependent; BAW,
bronchial alveolar wash; DTA, deep tracheal aspirate.
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resistance if the patient has been exposed to FL which
has a similar structure implying possible cross-resis-
tance. In our samples, out of the eight isolates that were
VO resistant, four were FL resistant suggesting a
possible secondary resistance through such a mecha-
nism. However, primary resistance cannot be ruled out
unless specific antifungal hospital treatment for each
patient is analysed and correlated with resistance. Such
an undertaking depends on the hospitals cooperation
and is not always feasible.
Caspofungin and resistance
The MIC range for CS obtained was the lowest compared
to the other antifungal drugs tested. Furthermore, the
MIC values of CS obtained were similar for the different
isolates and ranged from <0.002 to 0.38 lg ml)1.
However, an MIC of 0.38 lg ml)1 remains questioned
in the absence of interpretive breakpoints for CS. As this
study was conducted in Lebanon without any informa-
tion about the utilisation of CS by Lebanese hospitals
and before the clinical release of VO, and because all the
hospital isolates were susceptible to CS (MICs
<1 lg ml)1), we could, in part, either postulate that
the rate of primary resistance to CS is very low, or
eliminate the possibility of primary resistance in Leba-
nese isolates and thus any resistance that develops to
this drug in the future could be considered as secondary
resistance. It should be noted, however, that the lack of
universally approved interpretive breakpoints for CS
would limit our ability to confirm the presence of
primary and secondary resistance. Our results reveal
that resistance to azoles among Lebanese yeast clinical
isolates is so far preliminary and it is in favour of azole
therapy with continuous and cautious observation for
the development of resistance. However, these isolates
were overwhelmingly collected from sites of colonisation
rather than invasive sites and thus the possibility
remains that the susceptibility pattern among blood-
stream invasive isolates might differ. Nevertheless, it
should be noted that three samples were resistant to all
azoles including one sample that was resistant to three
out of four azoles used in this study and one sample, a
deep tracheal aspirate sample isolated from a patient in
cardiac arrest, was resistant to all azoles and AP.
Bearing in mind that CS was the only drug on which
this isolate showed no resistance, the use of CS in such
cases may prove critical in treatment and should be
recommended. However, CS treated patients should be
monitored with care because C. albicans resistance has
been reported in a patient with azole-refractory thrush-
oesophagitis that initially responded to CS but where the
treatment eventually failed and a correlation between
in vivo failure of CS therapy and in vitro rise in CS MIC
was recorded.51
Stevens [52] reported the reduced activity of CS
against C. albicans clinical isolates at high drug concen-
trations, which might pose a hesitating prophylactic use
of this drug if administered for long periods of time.
Whether this will be the case in Lebanese isolates
remains to be seen.
MTL homozygosity and drug resistance
Finally, the PCR screening of the MTL loci revealed that
all the hospital isolates were heterozygous at the MTL
locus (a ⁄ a) except for 11 isolates (9.5%) as shown in
Table 4. Of these, only one isolate was MTLa and the
remaining 10 were MTLa. Of the MTL homozygous
isolates, five (45.5%) were resistant to at least one azole
antifungal agent including one sample that was resis-
tant to all the azoles tested. Three samples were resistant
only to IT and the rest were susceptible. However, of the
105 C. albicans isolates heterozygous at the MTL locus,
only 14 (13.3%) were resistant to at least one of the
azole antifungal drugs. Our results reveal a strong
correlation between homozygosity at the MTL locus and
drug resistance (P = 0.02). Recently, Coste [53] showed
that acquisition of homozygosity of TAC1, the tran-
scriptional activator of the CDR pump, which is located
14 Kb from the MTL locus on chromosome 5, is
accompanied by MTL homozygosity contributing to
the azole resistant phenotype. However, it is the TAC1
homozygosity at chromosome 5 that mediates antifun-
gal resistance in C. albicans because hyperactive TAC1
alleles are codominant with wild type alleles and thus
cannot be expressed at high enough levels to confer
azole resistance as heterozygotes, but necessitates the
loss of the second, wild type allele. Our results support
this study and suggest that, even though drug resis-
tance might not be because of the MTL locus homozy-
gosity, its closeness to the TAC1 locus might make it a
useful marker for future resistance studies.
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